<SEC-DOCUMENT>0001144204-16-129622.txt : 20161026
<SEC-HEADER>0001144204-16-129622.hdr.sgml : 20161026
<ACCEPTANCE-DATETIME>20161026163102
ACCESSION NUMBER:		0001144204-16-129622
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20161026
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20161026
DATE AS OF CHANGE:		20161026

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SANGAMO BIOSCIENCES INC
		CENTRAL INDEX KEY:			0001001233
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				680359556
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30171
		FILM NUMBER:		161952936

	BUSINESS ADDRESS:	
		STREET 1:		501 CANAL BLVD
		STREET 2:		POINT RICHMOND TECH CNTR.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804
		BUSINESS PHONE:		5109706000

	MAIL ADDRESS:	
		STREET 1:		501 CANAL BLVD
		STREET 2:		POINT RICHMOND TECH CNTR.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v451312_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Washington,
DC 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>CURRENT
REPORT Pursuant</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>to
Section 13 or 15(d) of the</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Securities
Exchange Act of 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Date of report (Date
of earliest event reported) : <U>October 26, 2016</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 1pt solid"><B>SANGAMO
BIOSCIENCES, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in
Its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 1pt solid">Delaware</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or Other Jurisdiction of Incorporation)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 57%; font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>000-30171</B></FONT></TD>
    <TD STYLE="width: 43%; font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>68-0359556</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#9;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 56%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>501 Canal Blvd, Suite A100</B></FONT></TD>
    <TD STYLE="width: 44%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Richmond, California 94804</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of Principal Executive Offices)</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 1pt solid"><B>(510)
970-6000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&rsquo;s Telephone Number, Including
Area Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 0.75pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former Name or Former Address, if Changed
Since Last Report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (<I>see </I>General Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 2.02. Results of Operations and
Financial Condition. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.25in">On October 26, 2016,
Sangamo BioSciences, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2016. A copy
of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 9.01 Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Exhibits. &nbsp;&nbsp;The following material is filed as an exhibit
to this Current Report on Form 8-K:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exhibit No.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">99.1</TD><TD STYLE="text-align: justify">Press Release Issued October 26, 2016.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DATE: October 26, 2016</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SANGAMO BIOSCIENCES, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 54%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 41%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ ALEXANDER MACRAE</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alexander Macrae, M.B., Ch.B., Ph.D.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v451312_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head><META content="text/html; charset=utf-8"></META></head><body style="font-size:10pt;font-family:Arial;color:black;"><DIV STYLE="width: 100%; margin-left: 10pt; text-align: right"><B>Exhibit
                                         99.1</B></DIV>

<DIV STYLE="width: 100%; margin-left: 10pt">&nbsp;</DIV>

<DIV STYLE="width: 100%; margin-left: 10pt"><p style="text-align:center"><b>Sangamo BioSciences Reports Third Quarter 2016 Financial Results</b></p>
<br /><br />Company Highlights Progress of Key Clinical Programs in Hemophilia and Lysosomal Storage Disorders</div><div style="width:100%;margin-left:10pt;"><div style="margin:0;margin-top:16pt;"><p>RICHMOND, Calif., Oct. 26, 2016 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today reported its third quarter 2016 financial results and provided an update on recent events and development timelines for its therapeutic programs.</p><div id="prni_dvprnejpg2340leftMSAsset804605" style="TEXT-ALIGN: left; WIDTH: 100%"><img src="sf35903logo.jpg" id="prnejpg2340leftMSAsset804605" title="Sangamo BioSciences, Inc. (PRNewsFoto Sangamo BioSciences, Inc.)" border="0" alt="Sangamo BioSciences, Inc. (PRNewsFoto Sangamo BioSciences, Inc.)"
align="middle"></div><p>&#34;The third quarter of 2016 has been a pivotal time for Sangamo, as we worked to focus our efforts and execute on our prioritized therapeutic programs in hemophilia B, hemophilia A, MPS I and MPS II,&#34; said Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo&#39;s president and chief executive officer. &#34;I am pleased to announce that the Phase 1/2 clinical trial for SB-FIX, our <i>in vivo</i> genome editing program for hemophilia B, is open. We are also on track to file an IND application for our AAV cDNA Factor 8 gene therapy program for hemophilia A by the end of this year. In addition, we submitted the additional data package for our MPS I and MPS II programs to the FDA in September, and I am pleased to report that the FDA has cleared these programs for clinical development. Preparations are now underway to initiate Phase 1/2 clinical trials
for these indications in early 2017.&#34;</p><p>Dr. Macrae continued, &#34;We also made a number of organizational changes, including several key hires in our clinical and technical operations teams and instituted new procedures in order to position the company for clinical success. I am very encouraged by the commitment of our entire team and the progress we have made in the third quarter to drive these activities forward. I remain confident that we can demonstrate the value and therapeutic potential of our genome editing and gene therapy platforms and with reliable steps, make sensible progress and realize our vision of transforming Sangamo into a patient-focused therapeutics company.&#34;</p><p><b>Recent </b><b>Highlights</b></p><ul type="disc">
<li><b>Initiation of FIXtendz (SB-FIX-1501) Phase 1/2 clinical trial designed to assess safety, tolerability and potential efficacy of SB-FIX in adults with hemophilia B.</b> In October, Sangamo opened the first clinical study of an <i>in vivo</i> genome editing therapeutic, its Phase 1/2 clinical trial (FIXtendz, SB-FIX-1501). SB-FIX-1501 is an open-label, dose-escalation study in male subjects over eighteen years of age, with severe hemophilia B, who do not have inhibitors or hypersensitivity to recombinant Factor IX protein (rFIX). The study will enroll up to nine subjects in three dosing cohorts of two subjects per cohort, with additional subjects to be enrolled at the optimal therapeutic dose, and will evaluate the safety and potential efficacy of a single administration of SB-FIX. </li>
<li><b>U.S. Food and Drug Administration (FDA) grants orphan drug designation to SB-FIX, the first <i>in vivo</i> genome editing therapeutic in development. </b>In September, Sangamo announced that the FDA granted Orphan Drug Designation (ODD) to SB-FIX, the company&#39;s zinc finger nuclease (ZFN)-mediated <i>in vivo</i> genome editing therapeutic candidate for hemophilia B. Orphan drug designation is granted to investigational drugs and biologics that are intended to treat rare diseases that affect fewer than 200,000 people in the U.S. This designation helps facilitate drug development by providing several benefits to drug developers, including assistance with clinical study design and drug development, tax credits for qualified clinical trial costs, exemption from certain FDA application fees and seven years of market exclusivity upon regulatory product approval. </li>
<li><b>FDA clearance to initiate Phase 1/2 clinical trials for SB-</b><b>318 (MPS I) and SB-913 (MPS II) therapeutic programs. </b>Sangamo submitted the additional <i>in vitro</i> studies requested by the FDA in September and recently received clearance to initiate Phase 1/2 clinical trials for the Mucopolysaccharidosis Type I (MPS I, Hurler syndrome) and Mucopolysaccharidosis Type II (MPS II, Hunter syndrome) programs based on its ZFN-mediated <i>in vivo</i> genome editing therapeutic platform. The company expects to initiate the clinical studies in early 2017. </li>
<li><b>Appointment of new head of technical operations. </b>In August, Sangamo appointed Mohammad El-Kalay, Ph.D., as Vice President, Technical Operations. Dr. El-Kalay brings over 25 years of operational management experience in the life sciences field, including expertise in process development and cGMP manufacturing operations at clinical scale with hematopoietic stem cells, T-cells and various other cell types. Dr. El-Kalay is responsible for process development and manufacturing of all biotherapeutics for Sangamo. </li></ul><p><b>Third Quarter 2016 Results
<br /></b>For the third quarter ended September 30, 2016, Sangamo reported a consolidated net loss of $19.0 million, or $0.27 per share, compared to a net loss of $9.2 million, or $0.13 per share, for the same period in 2015. As of September 30, 2016, the Company had cash, cash equivalents, marketable securities and interest receivable of $155.4 million.</p><p>Revenues for the third quarter of 2016 were $2.8 million, compared to $8.6 million for the same period in 2015. Third quarter 2016 revenues were generated from the Company&#39;s collaboration agreements with Biogen and Shire International GmbH (Shire), enabling technology agreements and research grants. The revenues recognized for the third quarter of 2016 consisted of $2.7 million from collaboration agreements and $0.1 million from research grants, compared to $8.4 million and $0.2 million, respectively, for the same period in
2015. The decrease in collaboration agreement revenues was a result of an amendment to the Company&#39;s collaboration and license agreement with Shire in the third quarter of 2015, which returned the rights to the hemophilia programs to Sangamo, as well as a decrease in revenues from the Biogen agreement as the initial research phase of these programs has matured and activities during this quarter were largely internal.</p><p>In the third quarter of 2016, Sangamo recognized $1.2 million of revenues related to research services performed under the collaboration agreement with Biogen, and $0.2 million of revenues related to research services performed under the collaboration agreement with Shire. In addition, Sangamo received upfront payments of $13.0 million and $20.0 million pursuant to the agreements entered into with Shire in 2012 and Biogen in 2014, respectively. The Shire payment
is being recognized as revenue on a straight-line basis over the initial six-year research term. Beginning in January 2016, the Biogen payment is being recognized over approximately 42 months which reflects the revised service period related to Sangamo&#39;s deliverables under the Biogen agreement. The Company recognized $0.5 million of the Shire upfront payment and $0.6 million of the Biogen upfront payment as revenue for the third quarter of 2016.</p><p>Research and development expenses were $17.0 million for the third quarter of 2016, compared to $16.7 million for the same period in 2015. General and administrative expenses were $5.0 million for the third quarter of 2016, compared to $4.6 million for the same period in 2015.</p><p>Total operating expenses for the third quarter of 2016 were $22.0 million, compared to $21.3 million for the same period in 2015.</p><p><b>Nine Months
Results
<br /></b>For the nine months ended September 30, 2016, the consolidated net loss was $62.0 million, or $0.88 per share, compared to a consolidated net loss of $26.7 million, or $0.38 per share, for the nine months ended September 30, 2015. Revenues were $10.5 million for the nine months ended September 30, 2016, compared to $30.4 million for the same period in 2015. The decrease in revenues was primarily related to the amendment of our collaboration and license agreement with Shire, as well as a decrease in revenues related to our agreements with Sigma and Biogen. Total operating expenses were $73.2 million for the nine months ended September 30, 2016, compared to $61.6 million for the same period in 2015 and reflect increased expenses related to salaries and benefits, including stock-based compensation expense, as well as professional fees, consulting services and other corporate
costs.</p><p><b>Financial Guidance for 2016
<br /></b>The Company reiterates guidance as follows:</p><ul type="disc">
<li><b>Cash and Investments:</b> Sangamo expects that its cash, cash equivalents and marketable securities will be at least $140 million at the end of 2016, inclusive of research funding from existing collaborators but exclusive of funds arising from any additional new collaborations or partnerships, equity financings or other new sources. </li>
<li><b>Revenues: </b>Sangamo expects that revenues will be in the range of $12 million to $17 million in 2016, inclusive of research funding from existing collaborations. </li>
<li><b>Operating Expenses:</b> Sangamo expects that operating expenses will be in the range of $85 million to $95 million for 2016. </li></ul><p><b>Conference Call
<br /></b>Sangamo will host a conference call today, October 26, 2016, at 5:00 p.m. ET, which will be open to the public. The call will be webcast live and can be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations. A replay of the webcast will be available for two weeks after the call. During the conference call, the Company will review these results, discuss other business matters and provide guidance with respect to the remainder of 2016.</p><p>The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. The conference ID number for the call is 96289087.  A conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on October 26, 2016 to 11:59 p.m. ET on November 2, 2016. The conference call replay
numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 96289087.</p><p><b>About Sangamo
<br /></b>Sangamo BioSciences, Inc. is focused on Engineering Genetic Cures<sup>&#174;</sup> for monogenic and infectious diseases by deploying its novel zinc finger DNA-binding protein technology, in therapeutic genome editing and gene regulation, and AAV-based gene therapy platforms. The Company&#39;s proprietary ZFN-mediated <i>in vivo</i> genome editing approach is focused on monogenic diseases, including hemophilia and lysosomal storage disorders, including MPS I and MPS II. Sangamo has initiated a Phase 1/2 clinical trial for hemophilia B, the first <i>in vivo</i> genome editing application cleared by the FDA. In addition, Sangamo has Phase 1/2 and Phase 2 clinical programs in HIV/AIDS (SB-728). The Company has also formed a strategic collaboration with Biogen Inc. for hemoglobinopathies, including sickle cell disease and beta-thalassemia, and with Shire International GmbH to
develop therapeutics for Huntington&#39;s disease. It has established strategic partnerships with companies in non-therapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the Company&#39;s website at www.sangamo.com.</p><p><i>ZFP Therapeutic<sup>&#174;</sup> is a registered trademark of Sangamo BioSciences, Inc.</i></p><p><i>This press release contains forward-looking statements regarding Sangamo&#39;s current expectations. These forward looking statements include, without limitation, references to expected timing of initiating clinical trials, presentation of clinical trial data and submission of INDs, anticipated cash and investment balance, operating expenses, revenue and achievement of milestone and royalty payments under Sangamo&#39;s collaboration agreements, changes in internal organization,
the research and development of ZFNs and ZFP TFs, and the focus on clinical trials and therapeutic applications of Sangamo&#39;s gene therapy and ZFP technology platforms. These statements are not guarantees of future performance and success and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the early stage of ZFP Therapeutic development, the lengthy and uncertain regulatory approval process, uncertainties related to the timing of initiation and completion of clinical trials, whether clinical trial results will validate and support the safety and efficacy of ZFP Therapeutics, and the ability to maintain and establish strategic partnerships.  Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo and its
partners will be able to develop commercially viable gene-based therapeutics. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo&#39;s operations and business environments. These risks and uncertainties are described more fully in Sangamo&#39;s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.</i></p><p> </p><div>
<div><table style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt" cellspacing="0" cellpadding="0" border="0"><tr><td colspan="8" style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black"><b>SELECTED CONSOLIDATED FINANCIAL DATA</b></font></font></p></td></tr><tr><td colspan="8" style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font
style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">(unaudited; in thousands, except per share data)</font></font></p></td></tr><tr><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td></tr><tr><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td></tr><tr><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td colspan="3" style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">&#160;Three Months Ended&#160;&#160;</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td colspan="3" style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">&#160;Nine Months Ended&#160;&#160;</font></font></p></td></tr><tr><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td colspan="3" style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">&#160;September 30,&#160;</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td colspan="3" style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">&#160;September 30,&#160;</font></font></p></td></tr><tr><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">2016</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">2015</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">2016</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">2015</font></font></p></td></tr><tr><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black"><b>Statement of Operations Data:</b></font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom;
BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td></tr><tr><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">Revenues:</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td></tr><tr><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 12px; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">Collaboration agreements</font></font></p></td><td nowrap="nowrap" style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">$ &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;2,728</font></font></p></td><td
style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td nowrap="nowrap" style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">$ &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;8,406</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td nowrap="nowrap" style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">$ &#160;10,031</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td nowrap="nowrap" style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">$ &#160;28,878</font></font></p></td></tr><tr><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 12px; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">Research grants</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN:
bottom; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">95</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">163</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">436</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">1,540</font></font></p></td></tr><tr><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 24px; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">Total revenues</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom;
BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">2,823</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">8,569</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">10,467</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">30,418</font></font></p></td></tr><tr><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 24px; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td></tr><tr><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">Operating expenses:</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td></tr><tr><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 12px; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">Research and development</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">17,008</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom;
BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">16,694</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">51,728</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">47,292</font></font></p></td></tr><tr><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 12px; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">General and administrative</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom;
BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">5,021</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">4,560</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">21,468</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">14,309</font></font></p></td></tr><tr><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 24px; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">Total operating expenses</font></font></p></td><td style="BORDER-TOP: black 1pt solid; BORDER-RIGHT: 1pt;
VERTICAL-ALIGN: bottom; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">22,029</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: black; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">21,254</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: black 1pt solid; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">73,196</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: black; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">61,601</font></font></p></td></tr><tr><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">Loss from operations</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom;
BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">(19,206)</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">(12,685)</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">(62,729)</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">(31,183)</font></font></p></td></tr><tr><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">Interest and other income, net</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: black
1pt solid; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">238</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">101</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">668</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">406</font></font></p></td></tr><tr><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">Loss before taxes</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt;
TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">(18,968)</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">(12,584)</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">(62,061)</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">(30,777)</font></font></p></td></tr><tr><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">Benefit from income taxes</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt;
TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">3</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">3,339</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">27</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">4,087</font></font></p></td></tr><tr><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">Net loss</font></font></p></td><td nowrap="nowrap" style="BORDER-TOP: black 1pt solid; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM:
black 2pt double; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">$ &#160; &#160; &#160; &#160; &#160; &#160; &#160; (18,965)</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td nowrap="nowrap" style="BORDER-TOP: black 1pt solid; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: black 2pt double; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">$ &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;(9,245)</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td nowrap="nowrap" style="BORDER-TOP: black 1pt solid; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: black 2pt double; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">$(62,034)</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td nowrap="nowrap" style="BORDER-TOP: black 1pt solid; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: black 2pt double; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">$(26,690)</font></font></p></td></tr><tr><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">Basic and diluted net loss per common share</font></font></p></td><td nowrap="nowrap"
style="BORDER-TOP: black 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: black 2pt double; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">$ &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; (0.27)</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td nowrap="nowrap" style="BORDER-TOP: black 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: black 2pt double; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">$ &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;(0.13)</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td nowrap="nowrap" style="BORDER-TOP: black 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: black 2pt double; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">$ &#160; &#160;(0.88)</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td nowrap="nowrap" style="BORDER-TOP: black 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: black 2pt double; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">$ &#160; &#160;(0.38)</font></font></p></td></tr><tr><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td></tr><tr><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">Shares used in computing basic and diluted net loss per common share</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: black 2pt double; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">70,618</font></font></p></td><td style="BORDER-TOP:
1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: black 2pt double; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">69,892</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: black 2pt double; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">70,493</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: black 2pt double; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">69,622</font></font></p></td></tr><tr><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td></tr><tr><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td></tr><tr><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td></tr><tr><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td></tr><tr><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black"><b>SELECTED BALANCE SHEET DATA</b></font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td></tr><tr><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black"><u>September 30, 2016</u></font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black"><u>December 31, 2015</u></font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td></tr><tr><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td></tr><tr><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">Cash, cash equivalents, marketable securities and interest receivable</font></font></p></td><td nowrap="nowrap" style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">$ &#160; &#160; &#160; &#160; &#160; &#160; &#160;
155,398</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td nowrap="nowrap" style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">$ &#160; &#160; &#160; &#160; &#160; &#160; &#160;209,307</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td></tr><tr><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">Total assets</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">164,978</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right;
PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">217,235</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td></tr><tr><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 6pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">Total stockholders&#39; equity</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">143,836</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt;
TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt"><p style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black; MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Arial; COLOR: black">192,439</font></font></p></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td><td style="BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; PADDING-LEFT: 6pt; BORDER-LEFT: 1pt; PADDING-RIGHT: 8pt">
<br /></td></tr></table></div></div><p></p><p>Logo - http://photos.prnewswire.com/prnh/20130102/SF35903LOGO</p><p> </p>
<br /><br /><p>CONTACT: Sangamo BioSciences, Inc., Elizabeth Wolffe, Ph.D., (510) 970-6000, x271 OR Varant Shirvanian, (510) 970-6000, x205</p></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>sf35903logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sf35903logo.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0(" 0$" 0$! @(" @(" @(" 0(" @(" @(" @+_
MVP!# 0$! 0$! 0$! 0$" 0$! @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @+_P  1" !; 9 # 2(  A$! Q$!_\0
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M.T@[;R0%LD%?TB_X+17]G\0OV+?A3XZ\-746J>&[[XJ>!_%UAJ$ 9[>]\/\
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M,>!,ZX7\(O&["YBZ5#!X?B.ECLJY*D9SC&KC5!Q?*_<M&#M%*,KN[NM'^&\
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M7ABEWDG-N1@$'/\ .I_P3QNA\6O^"F-MXWL#(MIKGC+XT_$9;F,;?)TO6O\
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M+M%\."XMK1IO%GPM\$3>';B660>79W%]HFDL+>YDC^4(US&Q8_(^[ /[5_\
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M:VFQ_%K6;6(^$=,U/1I];M6\+P7GDR1RVMK=?Z/LVL#M;J17[[6,C)8VVX2
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M'>&?C;\:/%E[KLFB:#X_\2>*/%>LR^?=OI?AC5_$$DMU<W$QP%ATJP5$+$(
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M4EE"D?VGX@O;/3=2N ?XMU[XJE'&2?-SR 2/8_\ @N9XGOO%G[0GP/\ A?I
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MZ;_PDWDRV\<\5Q<:]XJO-)WR;\@K8OO (V[9-Q((JWX%^&__  5__8_TN_\
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MCGUBNM6U:0=L7V.H->%?\%[XXE^*/[.LX7$LO@;QZCL?[D.O^'D7..I+,/\
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M<ONVM[BO'_"[Z?.[\PA'E6C<9O[7--N/I>7O?.W8SXXMD)0K+MSQ'*ZY49)
M4D<+C 'H *F> .JA28VZDJ%+'@@#[O4 \$_K5GR8MH78-H)(';)ZTX(HZ*.!
M@>P]!Z"E.G&7,G"Z?7FDI/;XG_P_S&E+FYIM3FOMN*O+_$OA^X@13DC!((;.
MXJ=P(Y! '3/\_2HVB0G.,D)MQPJD$8Q\H^OYU;VKZ4;%]!TQ^%-1;2N_9-?R
MV=O-.4=^E[;=2?9WLIOG5[MM;_W;)I<OEY+0IB&,!% 967&PJ=Q4*-H&6&2.
M>_//%.DC&WYAN;MN5F*YXR!VJUL7T_G_ (TFQ",;1CTJ72C*W,E4[N48R;^:
M42TY*+CS:=$FXV7:]V_T\C*,$#E3(DFX#Y)%,L?EE"2"C*V8SR>1C.<'BG)
M)-RR^85)8G$R-G))! 5<KCH.]:0AC!!" $ @')X!Z]Z7RTY&T#/7'&?RINF[
M1BG'DCLG33Y5VBW+3\=2>5R</:>^ELW*;E'R3NN;U:78J,BNNU5XSRC,Z <G
M[H!P!P0?4'!R,BGV\(C8D$DE2",18R2O0QQKCA0,#CCIGFK(10, <?4_XTH
D'3^M/D]Y23<?[MHN/R;CS+Y-%)2Y8J4N9QZV<;^MI-/YG__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
